Ad
related to: converting from warfarin to apixabangoodrx.com has been visited by 100K+ users in the past month
Search results
Results from the WOW.Com Content Network
The structure of apixaban, before adjusting the moiety's for maximum potency. Apixaban. The 13F moiety intermediate before apixaban was fully developed. During the SAR development of apixaban there were three groups that needed to be tested to attain maximum potency and bioavailability.
The monitoring of warfarin and keeping the international normalized ratio (INR) between 2.0 and 3.0, along with avoiding over and under treatment, has driven a search for an alternative. [ 3 ] [ 14 ] A naturally occurring inhibitor of factor Xa was reported in 1971 by Spellman et al. from the dog hookworm. [ 15 ]
Compared to warfarin it has fewer interactions with other medications. [10] It is a direct factor Xa inhibitor. [6] In 2007, Pfizer and Bristol-Myers Squibb began the development of apixaban as an anticoagulant. [11] Apixaban was approved for medical use in the European Union in May 2011, and in the United States in December 2012.
ELIQUIS ® (apixaban) Demonstrates Consistent Reductions in Stroke and Systemic Embolism, Major Bleeding and Mortality Compared to Warfarin in Patients with Nonvalvular Atrial Fibrillation at ...
Bristol-Myers Squibb and Pfizer Announce Publication of ARISTOTLE Subanalysis in Circulation Subgroup analysis demonstrates that the treatment effects of Eliquis ® (apixaban) vs. warfarin, across ...
Subanalysis of Phase III ARISTOTLE Trial of Eliquis® (apixaban) Demonstrated Consistent Results Versus Warfarin in Patients with Nonvalvular Atrial Fibrillation with or without Valvular Heart ...
U.S. FDA Approves ELIQUIS ® (apixaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation ELIQUIS Demonstrated Superior Risk Reductions Versus ...
2159 14058 Ensembl ENSG00000126218 ENSMUSG00000031444 UniProt P00742 O88947 RefSeq (mRNA) NM_000504 NM_001312674 NM_001312675 NM_001242368 NM_007972 RefSeq (protein) NP_000495 NP_001299603 NP_001299604 NP_001229297 NP_031998 Location (UCSC) Chr 13: 113.12 – 113.15 Mb Chr 8: 13.09 – 13.11 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse Coagulation factor X (EC 3.4.21.6), or Stuart ...
Ad
related to: converting from warfarin to apixabangoodrx.com has been visited by 100K+ users in the past month